Enfortumab vedotin

About Astellas

Astellas Pharma is a major global pharmaceutical company with a mission to deliver innovative, patient-centric healthcare solutions. Formed in 2005 from the merger of Yamanouchi and Fujisawa, it has established a robust pipeline and commercial portfolio across oncology, urology, immunology, and other therapeutic areas. The company's strategy is built on a multi-modal R&D engine focused on cutting-edge biology, complemented by aggressive external innovation and a strategic push into digital health through its Rx+ and HealthX initiatives to drive sustainable growth.

About Astellas Pharma

Astellas Pharma is a Japan-based global pharmaceutical leader with a mission to deliver transformative therapies in areas of high unmet medical need. Formed by the 2005 merger of Yamanouchi and Fujisawa, the company has grown into a $45.8 billion market cap entity with a vertically integrated model spanning R&D, manufacturing, and global commercialization. Its strategy is anchored in a patient-centric approach, a robust pipeline, and strategic external innovation to drive growth in core therapeutic areas and next-generation modalities.

Therapeutic Areas

Other Urothelial Carcinoma Drugs